Loading organizations...
§ Public · Los Angeles, CA, USA
Late-stage clinical biopharmaceutical company developing transformative medicines primarily for immunology, prioritizing Thyroid Eye Disease.
ACELYRIN has raised $758.0M across 4 funding rounds.
Key people at ACELYRIN.
ACELYRIN has raised $758.0M in total across 4 funding rounds.
ACELYRIN is a late-stage clinical biopharmaceutical company focused on identifying, acquiring, and accelerating the development of transformative medicines for severe immunology conditions, based in Agoura Hills, California. The pre-revenue enterprise operates with a workforce of 83 employees and previously secured over $550 million across private venture rounds, including a $300 million Series C, before raising $540 million in a May 2023 initial public offering. Its institutional capitalization was driven by prominent healthcare investors such as Access Biotechnology, Westlake Village BioPartners, and Matrix Capital Management. Following a strategic pipeline restructuring to prioritize its lonigutamab candidate for thyroid eye disease over other clinical assets, the firm agreed to a corporate merger with Alumis in February 2025 at an estimated valuation of $320 million. ACELYRIN was founded in 2020 by Shao-Lee Lin and Bob Carey.
ACELYRIN has raised $758.0M across 4 funding rounds. Most recently, it raised $300.0M Series C in September 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2022 | $300M Series C | Access Biotechnology | Atlas Venture, Contrary Capital, Mott Family Capital, Matthew Mcaviney, Robert Garland, VenBio Partners, Westlake Village BioPartners, RON Pragides, Ayurmaya, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management | Announced |
| Jan 6, 2022 | $200M Venture Round | Alan Colowick | — | Announced |
| Nov 1, 2021 | $250M Series B | — | Contrary Capital, Mott Family Capital, Matthew Mcaviney, Robert Garland, VenBio Partners, Westlake Village BioPartners, RON Pragides | Announced |
| Dec 1, 2020 | $8M Series A | — | Contrary Capital, Mott Family Capital, Matthew Mcaviney, Robert Garland, Westlake Village BioPartners, RON Pragides | Announced |
Key people at ACELYRIN.
ACELYRIN has raised $758.0M in total across 4 funding rounds.
ACELYRIN's investors include Access Biotechnology, Atlas Venture, Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, venBio, Westlake Village BioPartners, Ron Pragides, AyurMaya, Cowen Healthcare Investments, Decheng Capital.
The premise of your query is incorrect: ACELYRIN is not a technology company, but rather a biopharma company[1][2].
ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines in immunology[1][2]. The company serves patients with immunological disorders by developing novel drug candidates designed to address unmet medical needs. Rather than building software or digital products, ACELYRIN's core mission centers on advancing pharmaceutical treatments through its clinical pipeline and therapeutic expertise.
The company is backed by OrbiMed Advisors, a prominent healthcare-focused private equity firm[1], which provides both capital and strategic support for drug development and commercialization efforts.
ACELYRIN's pipeline demonstrates focus in specialized therapeutic areas:
ACELYRIN operates within the broader trend of specialty biopharma consolidation, where private equity firms acquire and develop promising drug candidates that larger pharmaceutical companies may overlook. This model allows the company to focus resources on specific therapeutic areas—particularly immunology—where significant unmet patient needs exist. The timing aligns with increased investment in precision medicine and targeted immunological treatments.
